Richard A Monaghan

US Patent:

49686089, Nov 6, 1990

Filed:

Oct 7, 1987

Appl. No.:

7/105797

Inventors:

Robert A. Giacobbe - Lavallette NJ
Sagrario M. Del Val - Madrid, ES
Richard L. Monaghan - Somerset NJ
Robert E. Schwartz - Westfield NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 102
C12N 100
C12N 138
C12N 114

US Classification:

435 71

Abstract:

An antifungal agent produced by cultivation of Zalerion arboricola is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity. Its production and isolation are also described.

US Patent:

53188950, Jun 7, 1994

Filed:

Oct 5, 1992

Appl. No.:

7/956716

Inventors:

Jennifer N. Kahn - East Brunswick NJ
Kevin M. Byrne - West Trenton NJ
Louis Kaplan - New City NY
Richard J. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 118
C12N 100
C07D49800

US Classification:

435 32

Abstract:

Disclosed are new Aspergillus niger mutants which can be used for identifying active FK-506/ rapamycin type, or cyclosporin A type inununosuppressants in a broth, natural product extract, or composition exhibiting inununosuppressant activity. Specifically disclosed are the new mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A.